Company profile
Gossamer Bio, Inc.
NASDAQ: GOSS · Healthcare · Biotechnology
#440 of 1,418 Healthcare companies by revenuebottom-quartile growth
EA Score
24DFH 25DQ 15GM —SS 56
v0.1 · 55/100 weight · provisional
↑ workforce scale, market scale · ↓ Piotroski F, disclosure history
Methodology →Revenue TTM
$55.5M
Rev growth YoY (TTM)
-55.4%
Net income (FY)
-$170.4M
Employees
162
as of 2026-08-20
Market cap
$76.6M
as of 2026-08-20
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$48.5M$48.5M2025
Net income-$170.4M-$170.4M2025
Operating income-$170.7M-$170.7M2025
Total assets$172.2M$172.2M2025
Liabilities$295.0M$295.0M2025
Equity-$122.8M-$122.8M2025
Revenue trend
FY2024 – FY2025 · USD
FY24
FY24
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
License and Service0%
By geography
Not disclosed.
The read
What is Gossamer Bio, Inc.’s revenue?
Gossamer Bio, Inc. booked $48.5M in FY2025 revenue, contracting 58% year over year — slower than 84% of Healthcare companies we track, at a -351.5% net margin.
Peers · Healthcare
Charlotte's Web Holdings, Inc.44DLexicon Pharmaceuticals, Inc.59CBioqual, Inc.65BShoulder Innovations, Inc.42DEvome Medical Technologies Inc.——Protagonist Therapeutics, Inc.57CNeighbors
San Diego →Key facts
CEOFaheem Hasnain
SectorHealthcare
IndustryBiotechnology
HeadquartersSan Diego, CA
ExchangeNASDAQ: GOSS
Employees162
IPO date2019-02-08
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.